Charles River Laboratories International (CRL) 10-K Summary — Year Ended Dec 27, 2025
Charles River Laboratories reported a decline in revenue and a net loss for the period, while operating cash flow remained positive. The company faces ongoing legal proceedings and supply chain risks.
Key takeaway
Year ended Dec 27, 2025 · FY2025 10-K
Charles River Laboratories reported a decline in revenue and a net loss for the period, while operating cash flow remained positive. The company faces ongoing legal proceedings and supply chain risks.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$4B
Revenue reported for the fiscal year.
Operating income
$25.2M
Income from operations reported for the year.
Net income
-$144.3M
Net income reported for the year.
Operating cash flow
$737.6M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $4B | +12.3% |
| Dec 30, 2023 | $4.1B | +3.9% |
| Dec 28, 2024 | $4B | -1.9% |
| Dec 27, 2025 | $4B | -0.9% |
Business overview
The company operates in the life sciences industry, providing research models and services, including non-human primates, to support drug development. Its forward-looking statements reference expectations regarding the non-human primate supply chain and the industries it serves.
Financial performance
Revenue has decreased for two consecutive periods, and the company reported a net loss. Operating income was modest, but operating cash flow remained substantial.
Material risks
The company faces risks related to its non-human primate supply chain, as well as securities class action and derivative lawsuits filed against it and certain officers and directors.
Liquidity and capital
The company funds its operations primarily through cash flows from operations and recent divestitures, supplemented by long-term borrowings. Management believes existing liquidity is sufficient for the foreseeable future.
What to watch
The resolution of the securities class action and derivative lawsuits should be monitored in the next filing.